These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33470023)

  • 21. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab.
    Schmalzing M; Behrens F; Schwaneck EC; Koehm M; Greger G; Gnann H; Burkhardt H; Tony HP
    Medicine (Baltimore); 2020 May; 99(19):e20201. PubMed ID: 32384515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F
    Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.
    Berkhout LC; l'Ami MJ; Krieckaert CLM; Vogelzang EH; Kos D; Nurmohamed MT; Wolbink GJ; Rispens T
    Rheumatology (Oxford); 2020 Jul; 59(7):1703-1708. PubMed ID: 31691828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
    Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
    J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
    Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
    Naniwa T; Iwagaitsu S; Kajiura M
    Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.